AB Biotek’s adiDAO microencapsulated to help with metabolic disorders
AB Biotek’s new adiDAO microencapsulated optimises the delivery of the DAO enzyme.
Photo credit: Juice Flair/Shutterstock.com
AB Biotek Human Nutrition and Health (HNH) has launched adiDAO microencapsulated, a new ingredient format to help with the delivery of the DAO enzyme and allows it to be combined with other functional ingredients for the first time.
DAO (diamine oxidase) helps the body to break down dietary histamine, a molecule that is naturally present in all food types but is found in particularly high concentrations in fish, dairy products, cheese, and wine.
Increased levels of unmetabolised histamine in the blood stream may result in gastro-intestinal issues, skin conditions, lower urinary tract (LUTS) symptoms, fibromyalgia, migraine and attention deficit hyperactivity disorder (ADHD). DAO deficiency is one of the world’s most common enzyme-related metabolic disorders.
According to AB Biotek, there is growing interest in solutions that enhance histamine degradation by increasing levels of DAO in the gut. DAO is sensitive to stomach pH, necessitating the use of delivery mechanisms that are gastro-resistant. In addition, DAO tends to interact with other bioactive ingredients in a way that diminishes its benefits.
AB Biotek HNH’s latest innovation offers a unique solution to both challenges. In adiDAO microencapsulated, the DAO is surrounded by two food-grade protective layers produced using a combination of coating technologies. These layers are specially designed to protect the DAO, optimising its delivery when it reaches the small intestine. The layers also help to prevent against undesirable interactions with other bioactive ingredients.
The technology creates new opportunities for developing innovative products in both the pharmaceutical and nutraceutical spaces. For example, it will enable manufacturers to include DAO in anti-histamine and ADHD treatments, or to combine it with probiotics or prebiotics in supplements.
Compatible with various pharmaceutical actives in different concentrations, adiDAO microencapsulated can be used to create bespoke, targeted solutions, offering convenience and improve patient compliance. Other benefits include a simplified production process and reduced manufacturing costs versus traditional gastro-resistance coating methods.
Gerald Dard, managing director at AB Biotek HNH, noted that rising awareness of DAO deficiency and related health issues is driving demand for innovative new solutions using DAO.
“Our adiDAO microencapsulated break new ground in this growing market, allowing manufacturers to combine other actives directly with DAO for the first time,” Dard explained. “It’s not just a flexible solution, but also a major technological leap forward with the potential to improve real outcomes for the many people affected by DAO deficiency.”
New adiDAO microencapsulated are suitable for tablets, stick packs, liquid suspension formats, gummies, and capsules. For more information, visit https://bit.ly/adiDAO-microencapsulated.
The format will be discussed at the Global DAO Congress on April 11th. More details at https://globaldaocongress.org/
